MISSION VIEJO, CA -- (Marketwired) -- 06/26/13 -- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
•Data presented at 7th Annual NIH CounterACT Network Research Symposium •AEOL 10150 improved survival up to 82 percent over 48 hours after exposure •The improvement in survival correlated with clinical scores, blood oxygenation and airway obstruction •Aeolus plans to meet with the FDA and discuss a pivotal trial design and an acceptable second species for approval under "the Animal Rule"
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that researchers from National Jewish Health, the University of Colorado and the US Army Medical Research Institute for Chemical Defense ("USAMRICD") have completed third and fourth studies confirming that AEOL 10150 provides significant lung protection and significantly improves survival in rats exposed to whole mustard gas. Data were presented at the 7th Annual CounterACT Countermeasures Against Chemical Threats Network Research Symposium in Washington, D.C. There are currently no effective treatments for mustard gas exposure and AEOL 10150 is a major focus of a sponsored research grant awarded by the National Institutes of Health ("NIH") CounterACT program to the University of Colorado and National Jewish Health to identify an effective treatment. Sulfur mustard gas has been used in warfare since World War I and continues to pose a threat to civilian and military personnel. Mustard gas exposure can cause blistering of the skin as well respiratory injury, fibrosis and death.
"AEOL 10150 continues to demonstrate significant protective effects in rescuing the lung against the deleterious effects of sulfur mustard vapor resulting in major improvements in survival and lung function," stated Brian Day, PhD, Professor and Vice Chair of Research the Department of Medicine at National Jewish Health and Investigator for the CounterACT Center of Excellence in Denver, and Chief Science Officer of Aeolus Pharmaceuticals, Inc. "These data affirm our earlier studies where AEOL 10150 protected the lung against sulfur mustard and the half-mustard, 2-chloroethyl ethylsufide."
Protects Lungs When Administered After Exposure
Four separate studies using 85 rats and comparing 2 different AEOL 10150 dosing regimens conclusively demonstrated that AEOL 10150 improves survival against an LD60-70 sulfur mustard gas exposure. AEOL 10150 improved sulfur mustard gas survival up to 82% over 48 hours. The improvement in survival seen with AEOL 10150 treated animals after sulfur mustard gas exposure correlated with improvements in clinical scores, blood oxygenation and airway obstruction. The best improvements in survival and lung function occurred with the AEOL 10150 dosing regimen of 5 mg/kg body weight given every 4 hours by subcutaneous injection (p < 0.0004).
Most Popular Stories
- Networks Vie for U.S. Hispanic TV Viewers
- Ad Counts Rise in 2013 for Hispanic Magazines
- 2014 World Cup Official Noisemakers Quieter than Vuvuzelas
- Saab Gets Back into the Game; U.S. Auto Sales Soar
- Dell Offers Undisclosed Number of Employee Buyouts
- Authorities Close to Deal with JPMorgan Chase over Madoff Response
- Apple Activates Customer-Tracking iBeacon
- 2013 Tech Gift Guide: iPad Mini Still Hot; Chromecast a Great Low-Cost Option
- It's No Yolk: Food-tech Startups Take Aim at Replacing Eggs
- A Biography of Jonathan Ive, Apple's Creative Chief